GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
424

13 months in and CGM is still the thing I get wrong

Results The Quiet One ×5

13 months in and CGM is still the thing I get wrong, and the part I actually want to talk about is at the bottom.

Pulling the figures out of the title: 13 months. All of it is written down as it happened rather than reconstructed.

On hypoglycaemia, because the risk gets attributed to the wrong thing constantly.

Incretin-based agents stimulate insulin secretion in a glucose-dependent way: the effect scales with glycaemia rather than acting unconditionally. That is why monotherapy risk is low. Where risk rises substantially is in combination with agents that lower glucose independently of the current level.

Which means the question "does this cause hypos" is not answerable without knowing the rest of the regimen — and that the person who can answer it is the one who wrote the regimen. Nothing on this board is a substitute for that conversation, and the good threads here end by saying so.

The order things move in, since nobody explains it and it worries people.

Postprandial excursions generally respond earliest. Variability tends to narrow before the average does, which is visible on a sensor and invisible on a lab result. Fasting glucose is often the laggard, and A1c — being a three-month average — is the last thing to reflect anything.

So a month in which the sensor looks better and the fasting number has not moved is the ordinary sequence, not a contradiction. Knowing that in advance would have saved me a quarter of unnecessary worry, which is why it is worth writing down.

Ask me anything specific. Anything general I will probably get wrong.

435 up / 11 down98% upvoted17 commentsid y1opcd13 Sep 2024

17 comments

10 in this archive, depth 4

best — the order this archive was captured in

u/laila_wikstrom86 points·1 year ago

Continuous monitoring shows the shape: postprandial excursions, overnight behaviour and time in range. Two people with identical A1c can have very different distributions.

replysharereportpermalink
u/tomas_kimani19 points·1 year ago·edited

Continuous monitoring shows the shape: postprandial excursions, overnight behaviour and time in range.

Adding the obvious one — bring the export, not the single number, to whoever manages this.

replysharereportpermalink
u/plain_titration6 points·1 year ago

How long between the two A1c measurements?

replysharereportpermalink
u/stubborn_batchlist_maybeOP-34 points·1 year ago

How long between the two A1c measurements?

Disagreeing with this line: that endpoint is from the obesity programme and does not answer the question.

replysharereportpermalink
u/karim_ramos64 points·1 year ago

Agreed on variability. Two people with the same average can have completely different days.

replysharereportpermalink
u/kaia_cabrera52 points·1 year ago

Certain conditions affect A1c independently of glycaemia. If a result looks inconsistent with the sensor data, that is a question for whoever manages your care rather than for this board.

replysharereportpermalink
u/sigrid_kaufmann14 points·1 year ago

Yes — the person managing your diabetes is the one to talk to, and this board is explicit about that.

replysharereportpermalink
u/tomas_lokken24 points·1 year ago

Certain conditions affect A1c independently of glycaemia.

Agreed, and the glucose-dependence point is the reason the risk profile reads the way it does.

replysharereportpermalink
u/appeal_letter_al18 points·1 year ago

Is that a first-day sensor reading?

replysharereportpermalink
u/bianca_demir16 points·1 year ago

Small fix — insulin secretion in this class is glucose-dependent, which is precisely why the risk you describe comes from the other agent.

replysharereportpermalink
About c/t2dglp1

Type 2 diabetes as the original indication: A1c trajectories, CGM traces, hypoglycaemia risk when stacked with sulfonylureas or insulin, metformin combinations, and why the weight-loss conversation sometimes drowns out the glycaemic one.

36kmembers
62submissions
Jun 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/t2dglp1 rules
  1. Insulin and sulfonylurea interactions are a real hypo risk. Do not hand-wave them.
  2. Post A1c with units and the assay date.
  3. No medication-stopping advice. Ever.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.